samedan logo
 
 
 
spacer
home > pmps > spring 2019 > the importance of product master data
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Importance of Product Master Data

By November 2019, wholesale distributors will be required to verify the serialised product identifiers for any saleable products that have been returned to them before they can be restocked and resold. With this new saleable returns verification requirement, the challenges of master data exchange for manufacturers will come to the fore.

To manage the scope, scale, and challenges of the saleable returns requirement, wholesalers and manufacturers must re-evaluate their current methods of exchanging product master data information.

The Scale of the Challenge

The national organisation representing primary wholesale distributors in the US, the Healthcare Distribution Alliance (HDA), executed analysis of saleable returns. This showed that approximately 60 million units of drug product are returned annually, with the majority of saleable returns caused by overstocking (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dan Walles is the General Manager of Track & Trace and Compliance at TraceLink, where he brings more than 20 years of experience in product management, solution consulting, and service delivery to his role. He has focused exclusively on the needs of the life sciences industry for the past 15 years. Since joining TraceLink in 2010, Dan has been instrumental in educating customers on TraceLink’s Life Sciences Cloud and partner ecosystem to enable compliance and added business value through supply chain visibility and improved patient outcomes.
spacer
Dan Walles
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IONTAS announces a new collaboration to identify novel immunotherapy targets

Cambridge, UK, 07 May 2020: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Inotrem, a specialist in immunotherapy for acute and chronic inflammatory syndromes. As part of the agreement, IONTAS will apply its Mammalian Display technology to identify antibodies involved in the TREM-1 pathway.
More info >>

White Papers

Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites

ArisGlobal

ArisGlobal LLC Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement